May 23, 2023 / 09:00PM GMT
Operator
Thank you for standing by, and welcome to the MOVE-FA top line results. (Operator Instructions) As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Dr. Matthew Klein, Chief Executive Officer. Please go ahead, sir.
Matthew B. Klein - PTC Therapeutics, Inc. - CEO & Director
Thank you all for joining this afternoon's call. We had a number of updates today, and we wanted to take this time to discuss the top line results of the MOVE-FA study and the announced portfolio prioritization decisions. Before I begin, I refer you to our forward-looking statements on this slide, which are also posted on our website as well as our Risk Factors section in our most recent 10-K.
The MOVE-FA study was a 72-week placebo-controlled trial of vatiquinone for the treatment of Friedreich ataxia patients. As we have previously discussed, the trial was designed to focus on pediatric patients, given the strong safety profile of vatiquinone established in children, the natural history data demonstrating that younger FA
PTC Therapeutics Inc MOVE-FA Topline Results-Call Transcript
May 24, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers